Zacks Investment Research cut shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) from a buy rating to a hold rating in a research report report published on Monday.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Asterias Biotherapeutics (NYSEMKT:AST) opened at 4.35 on Monday. The company’s 50-day moving average is $4.58 and its 200-day moving average is $3.83. The firm’s market capitalization is $201.94 million. Asterias Biotherapeutics has a 52-week low of $2.30 and a 52-week high of $5.80.

Asterias Biotherapeutics (NYSEMKT:AST) last posted its earnings results on Monday, November 14th. The company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.07. The company had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.50 million. On average, analysts predict that Asterias Biotherapeutics will post ($0.77) EPS for the current year.

WARNING: This article was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The original version of this article can be accessed at http://www.watchlistnews.com/asterias-biotherapeutics-inc-ast-cut-to-hold-at-zacks-investment-research/1083702.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in Asterias Biotherapeutics during the fourth quarter worth approximately $102,000. Highbridge Capital Management LLC bought a new position in Asterias Biotherapeutics during the third quarter worth approximately $151,000. KCG Holdings Inc. increased its position in Asterias Biotherapeutics by 273.3% in the third quarter. KCG Holdings Inc. now owns 72,989 shares of the company’s stock worth $309,000 after buying an additional 53,438 shares during the period. Northeast Financial Consultants Inc increased its position in Asterias Biotherapeutics by 1,990.6% in the third quarter. Northeast Financial Consultants Inc now owns 732,265 shares of the company’s stock worth $3,105,000 after buying an additional 697,239 shares during the period. Finally, BlackRock Investment Management LLC increased its position in Asterias Biotherapeutics by 12.2% in the third quarter. BlackRock Investment Management LLC now owns 82,269 shares of the company’s stock worth $349,000 after buying an additional 8,962 shares during the period.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.